The lesser-known psychedelic drug is Ariadne (Dimoxamine, al-Et-DOM), 4C-D, a-ethyl-2C-D or 4-methyl-2,5-dimethoxy-alpha-ethylphenethylamine, 2,5-dimethoxy-4-methyl-butanphenamine, a-Et-2C-D. It is a 2C-D and DOM homologue. Ariadne was synthesized by Alexander Shulgin for the first time. Shulgin reported testing Ariadne up to a dose of 32 mg in his book PiHKAL (Phenethylamines I Have Learned And Loved), and reported that she develops psychedelia at a bare threshold. Apart from Shulgin’s restricted testing, very little evidence exists regarding the pharmacological properties, metabolism, and toxicity of Ariadne in humans.
However, alpha-Et-DOM has been shown to generate stimulus generalization in rats conditioned to react to the drug MDMA in more recent animal studies. This indicates that while alpha-Et-DOM may lack hallucinogenic effects, if used at higher dose levels than those tested by Shulgin, it could potentially produce empathogenic effects similar to those of MDMA (the potency of alpha-Et-DOM in this study was similar to that of MDMA, 1.5 mg/kg, which would be equivalent to a human dose of ~100 mg).